Description: Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
Home Page: medite-group.com
10524 Moss Park Road
Orlando,
FL
32832
United States
Phone:
407-996-9630
Officers
Name | Title |
---|---|
Mr. Jeffrey Rencher | Chief Marketing & Bus. Devel. Officer |
Ms. Susan Weisman | Consultant |
Exchange: PINK
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Health Care Equipment & Services |
GIC Industry: | Health Care Equipment & Supplies |
GIC Sub-Industry: | Health Care Equipment |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.2114 |
Price-to-Sales TTM: | 0.1056 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 69 |